Erin Barrett, MD
Dermatology · Omaha, NENPI 1427319912
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $70,969 of the $96,178 with a category attached, or 73.8%. 6 manufacturers reported payments, led by Sanofi at 45.1% of the total. 2025 is the largest year on record at $94,675, more than ten times the $51 reported in 2019. Among dermatology clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 92 payments — averaging $1045.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$43K
- Regeneron$27K
- Regeneron Healthcare Solutions, Inc.$26K
- Sun Pharmaceutical Industries Inc.$53
- AbbVie$26
- Lilly USA, LLC$19
Across 18 payments — averaging $2631.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$47K
What the payments were for
- Consulting fees$70,96974%
- Speaking & faculty fees$15,37216%
- Travel & lodging$7,6298%
- Food & beverage$2,2092%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 16 | $43,404 |
| Regeneron | 36 | $26,649 |
| Regeneron Healthcare Solutions, Inc. | 37 | $26,028 |
| Sun Pharmaceutical Industries Inc. | 1 | $53 |
| AbbVie | 1 | $26 |
| Lilly USA, LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$72,684
How this compares
$96,178 in reported general payments places this provider in the 95th percentile of 68 dermatology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 26 | $332,515 |
| Dupixent PenDupilumab | 52 | $227,364 |
| Clobetasol Propionate | 32 | $1,752 |
| Clindamycin Phosphate | 23 | $1,285 |
| Triamcinolone Acetonide | 55 | $1,220 |
| Dapsone | 13 | $800 |
| Doxycycline Monohydrate | 21 | $551 |
| Minoxidil | 54 | $487 |
| Ketoconazole | 19 | $440 |
| Nystatin | 25 | $306 |
| Mupirocin | 39 | $284 |
| Metformin Hcl ErMetformin Hcl | 14 | $160 |
| Prednisone | 20 | $99 |
| Hydrocortisone | 16 | $89 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Omaha
- Rachel PersonOmaha$98K
- Joel SchlessingerOmaha$89K
- Mathew DaveyOmaha$35K
- Gage RenschOmaha$11K
- Herschel StollerOmaha$10K
- Deirdre StolmeierOmaha$10K
- Melissa DarlingOmaha$10K
- Christopher HuerterOmaha$7K
- Tina KinsleyOmaha$7K
- Sara StephensonOmaha$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.